

=== SOURCE: primary.html ===

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
CURRENT REPORT
Pursuant to Section 13 OR 15 (d)
of The Securities Exchange Act of 1934
Date of report (Date of earliest event reported): July 28, 2023
BIOGEN INC.
(Exact Name of Registrant as Specified in Charter)
Delaware
0-19311
33-0112644
(State or Other Jurisdictionof Incorporation)
(CommissionFile Number)
(IRS EmployerIdentification No.)
225 Binney Street , Cambridge , Massachusetts 02142
(Address of Principal Executive Offices and Zip Code)
Registrant’s telephone number, including area code: (617)
Check the appropriate box below if the Form filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☒	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Soliciting material pursuant to under the Exchange Act (17 CFR
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
communications pursuant to under the Exchange Act (17 CFR 240.14d
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
communications pursuant to under the Exchange Act (17 CFR 240.13e
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule of the Securities Exchange Act of 1934 (17 CFR
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Securities registered pursuant to Section 12(b) of the Act:
Title of each class		TradingSymbol(s)		Name of each exchangeon which registered
Common Stock, $0.0005 par value		BIIB		The Nasdaq Global Select Market
Title of each class
TradingSymbol(s)
Name of each exchangeon which registered
Item 1.01.	Entry into a Material Definitive Agreement.

=== Item 1.01. ===

Entry into a Material Definitive Agreement.
Agreement and Plan of Merger
On July 28, 2023, Biogen Inc. (“”), River Acquisition, Inc. (“”), a Delaware corporation and a wholly-owned subsidiary of Biogen and Reata Pharmaceuticals, Inc. (“”) entered into an Agreement and Plan of Merger (the “”), pursuant to which, and upon the terms and subject to the conditions set forth therein, Merger Sub will be merged with and into Reata (the “”), with Reata surviving the Merger as a wholly-owned subsidiary of Biogen.
The Merger Agreement was unanimously approved by Biogen’s Board of Directors (the “”). Reata’s Board of Directors (the “”) has unanimously (i) determined that the Merger Agreement and the transactio